CPP
ITCI

Crow Point Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Crow Point Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,499
Closed -$86K – 144
2019
Q3 		$86K Hold
11,499
– – 0.01% 121
2019
Q2 		$149K Hold
11,499
– – 0.02% 113
2019
Q1 		$140K Hold
11,499
– – 0.02% 112
2018
Q4 		$130K Hold
11,499
– – 0.02% 115
2018
Q3 		$250K Buy
11,499
+881
+8% +$18.4K 0.04% 131
2018
Q2 		$189K Buy
10,618
+8,875
+509% +$180K 0.04% 113
2018
Q1 		$37K Buy
1,743
+295
+20% +$5.75K 0.01% 218
2017
Q4 		$22K Buy
+1,448
New +$22.4K ﹤0.01% 243

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crow Point Partners's ITCI Position: Q4 2019 in Review

Crow Point Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2019, closing a stake of 11,499 shares — an estimated $86K sold.

Crow Point Partners first reported a position in ITCI in Q4 2017 and held it in 8 quarters. The position peaked at $250K in Q3 2018. 133 funds tracked by Wall St. Rank hold ITCI as of Q4 2019.

  • Crow Point Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2019 after selling out during the quarter.
  • Crow Point Partners sold 11,499 Intra-Cellular Therapies Inc. shares in Q4 2019, an estimated $86K.
  • Crow Point Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and held it in 8 quarters.
  • Crow Point Partners's Intra-Cellular Therapies Inc. position peaked at $250K in Q3 2018.
  • 133 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.